4Rowhani-Rahbar A, Mao C,Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine [ J ]. Vaccine, 2009,27 (41) :5612-5619.
5Mao C, Koutsky LA, Auh KA, et al. Efficacy of human papillomavims-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial [J]. Obstet Gynecol,2006,107( 1 ) :18-27.
6Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus ( HPV ) -16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types ( PATRICIA ) : final analysis of a double-blind, randomised study in young women [ J ]. Lancet, 2009,374 (9686) : 301-314.
7GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, et al. Sustained efiqcacy and immunogenicity of the human papillomavirus ( HPV )-16/18 AS04-adjuvanted vaccine : analysis of a randomised placebo-controlled trial up to 6.4 years [ J ]. Lancet ,2009,374(9706) : 1975-1985.
8Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant [ J ]. J Adolesc Health, 2007,40 ( 6 ) : 564 -571.
9Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04- adjuvanted prophylactic celvical cancer vaccine in women aged 15-55 years [J]. Vaccine,2009,27(4) :581-587.
10Garland SM, Hemandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavims toprevent anogenital diseases [ J ]. N Engl J Med,2007, 356(19) : 1928-1943.
